BioSpace News Archive

EyePoint Pharmaceuticals, Inc. today announced that the first patient has been dosed in the Phase 2 PAVIA clinical trial of EYP-1901.

C4 Therapeutics, Inc. today announced it has received a Study May Proceed Letter from the United States Food and Drug Administration (FDA) to begin a Phase 1/2 trial for CFT1946, an orally bioavailable mutant-selective BiDAC™ degrader for the treatment of BRAF-V600 mutant solid tumors.

PharmaTher Holdings Ltd. today released business highlights and audited financial results for its fiscal year ended May 31, 2022.

Lucira Health, Inc. announced interim results of a pilot study to evaluate the performance of their combined Chlamydia trachomatis and Neisseria gonorrhoeae assays integrated into the instrument-free at-home Lucira molecular test platform.

AN2 Therapeutics, Inc. today announced the award of a contract valued up to $17.8 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance the development of epetraborole for acute systemic melioidosis.

Pluri Inc. today issued the following update to shareholders from Chief Executive Officer and President Yaky Yanay announcing that it had signed its second technology collaboration agreement centered on Pluri’s 3D cell expansion platform and providing some financial status updates.

AbbVie (NYSE: ABBV) today revealed the spectrum of new data from studies of risankizumab (SKYRIZI®) in Crohn’s disease and upadacitinib (RINVOQ®) in ulcerative colitis and Crohn’s disease that will be presented as live presentations and e-Posters at the United European Gastroenterology (UEG) Week 2022, October 8-11 in Vienna and online.

Two distinctive platforms will streamline the antibody development process. With an advanced design and high binding affinity, S-DUAL™ ensures optimized manufacturability of bispecific antibodies.

Kling Biotherapeutics announces the dosing of the first patient with KBA1412 in its Phase 1b trial.

NuVasive, Inc. has announced the planned agenda for the Company’s Investor Day 2022, which will be hosted at the NuVasive West Coast Experience Center in San Diego on Thursday, October 6, 2022, with presentations beginning at 9:00 a.m. PT.